Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

IntroductionPyrotinib plus capecitabine has been approved in China for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Meanwhile, vinorelbine is another important chemotherapy option for MBC available in oral and intravenous forms. Thus, pyrotinib plus vinore...

Full description

Bibliographic Details
Main Authors:	Yi Li, Yixuan Qiu, Huihui Li, Ting Luo, Wei Li, Hong Wang, Bin Shao, Biyun Wang, Rui Ge
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Subjects:	human epidermal growth factor receptor 2 positive metastatic breast cancer pyrotinib vinorelbine tyrosine kinase inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.664429/full

Similar Items

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
by: Yizhao Xie, et al.
Published: (2021-08-01)

Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis
by: Hao Liao, et al.
Published: (2021-05-01)

Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report
by: Zi-yan Yang, et al.
Published: (2020-10-01)

Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
by: Hong-Shuai Li, et al.
Published: (2020-10-01)

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
by: Changjun Wang, et al.
Published: (2020-07-01)

Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
by: Lili Zhang, et al.
Published: (2021-07-01)

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
by: Anjie Zhu, et al.
Published: (2021-08-01)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
by: Xinyong Zhang, et al.
Published: (2020-07-01)

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
by: Zuhua Chen, et al.
Published: (2020-08-01)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01)

A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
by: Liu J, et al.
Published: (2021-09-01)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
by: Chaokun Wang, et al.
Published: (2021-05-01)

Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer
by: Yin Y, et al.
Published: (2020-12-01)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2020-05-01)

Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
by: Le-Tian Huang, et al.
Published: (2019-12-01)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2021-03-01)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
by: Sun Y, et al.
Published: (2021-09-01)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
by: Li X, et al.
Published: (2021-07-01)

Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget’s Disease Harboring Triple Uncommon HER2 Mutation: A Case Report
by: Guo JJ, et al.
Published: (2020-06-01)

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
by: Xinghao Ai, et al.
Published: (2021-09-01)

Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies
by: Fausto Petrelli, et al.
Published: (2011-12-01)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
by: D. J Ouyang, et al.
Published: (2021-08-01)

Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults
by: Liu Y, et al.
Published: (2021-06-01)

Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study
by: Ding K, et al.
Published: (2021-01-01)

The role of autophagy in human lung cancer cell line A549 induced by Vinorelbine
by: Xiao FU, et al.
Published: (2008-06-01)

Vinorelbine plus Oxaliplatin versus Vinorelbine plus Cisplatin for Advanced Non-small Cell Lung Cancer: A Systematic Review
by: Kehu YANG, et al.
Published: (2010-02-01)

Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report
by: Jun Ni, et al.
Published: (2021-04-01)

MODERN POSSIBILITIES OF APPLICATION OF PREPARATION NAVELBINE® IN THE TREATMENT OF METASTATIC BREAST CANCER
by: L. V. Bolotina
Published: (2016-06-01)

Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
by: Yanyan Wu, et al.
Published: (2020-07-01)

The Effect and Mechanism of Vinorelbine on Cisplatin Resistance  of Human Lung Cancer Cell Line A549/DDP
by: Chunsheng QI, et al.
Published: (2014-02-01)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2021-08-01)

Metastatic Intimal Sarcoma of the Pulmonary Artery Sensitive to Carboplatin-Vinorelbine Chemotherapy: Case Report and Literature Review
by: Marie Cantaloube, et al.
Published: (2018-01-01)

Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer
by: Yang ZHOU, et al.
Published: (2015-06-01)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2020-03-01)

Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma
by: Zhongben Tang, et al.
Published: (2021-03-01)

PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER: ROLE IN CLINICAL PRACTICE
by: G. M. TELETAEVA, et al.
Published: (2016-12-01)

Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report
by: He L, et al.
Published: (2020-08-01)

Gemcitabine Combined with Vinorelbine in the Treatment of Refractory Patients with Advanced Non-small Cell Lung Cancer: A Multi-center Retrospective Study
by: Shun LU, et al.
Published: (2012-09-01)

Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib
by: Gao Z, et al.
Published: (2019-04-01)

Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
by: Zhen Liu, et al.
Published: (2021-02-01)